A new drug application has been resubmitted to the FDA for the combination of camrelizumab and rivoceranib as a first-line ...

During a Case-Based Roundtable® event,  Michael R. Bishop, MD, moderated a discussion on monitoring and treatment of chronic ...

Findings from the phase 3 SIERRA study showed that Iomab-B was associated with a higher durable complete response rate vs ...

Nancy Lin, MD, discusses the efficacy of T-DXd for brain metastases as seen in DESTINYBreast-12 compared with other agents.

During a Case-Based Roundtable® event, Laahn Foster, MD, discussed the 2024 update to the RELATIVITY-047 trial in advanced ...

Analysis of the TROPION-Breast01 study showed that treatment with Dato-DXd did not significantly improve overall survival compared with chemotherapy in HR-positive, HER2-low or -negative breast cancer ...

The FDA granted fast track designation to EO-3021 for the treatment of advanced or metastatic gastric and gastroesophageal ...

During a Case-Based Roundtable® event, Michael J. Birrer, MD, PhD, moderated a discussion on what factors affect the need for ...

Efficacy findings from the phase 2 AGAVE-201 support the use of axatilimab, which was approved by the FDA for recurrent or ...

During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen ...

During a Case-Based Roundtable® event, Virginia F. Borges, MD, MMSc, discussed treatment selection for a patient with ER+, ...

During a Case-Based Roundtable® event, Ajay Nooka, MD, MPH, discussed adverse events related to talquetamab for multiple ...